Nivolumab/Ipilimumab Approved for Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Nivolumab/Ipilimumab Approved for Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
The combination of nivolumab and ipilimumab (Opdivo and Yervoy, respectively, Bristol-Myers Squibb Co.) has received approval as first-line treatment for intermediate and poor-risk advanced renal cell carcinoma (RCC). Approval was contingent on findi...

Everolimus Receives Approval for TSC-Related Seizures

Everolimus Receives Approval for TSC-Related Seizures
Everolimus (Afinitor Disperz, Novartis Pharmaceuticals Corp.) has received FDA approval for use in adults and pediatric patients 2-years and older who experience partial-onset seizures associated with tuberous sclerosis complex (TSC). TSC causes tumo...

Antiemetic Guideline Adherence: Challenges and Opportunities for Oncology Nurses With Rebecca Clark-Snow, RN, BSN, OCN

Antiemetic Guideline Adherence: Challenges and Opportunities for Oncology Nurses With Rebecca Clark-Snow, RN, BSN, OCN
The introduction of effective antiemetic regimens in recent years has led many clinicians to assume that CINV is no longer a major problem. However, nausea and vomiting are frequent complications of cancer treatment, occurring in up to 80% of patient...

Trastuzumab Plus Chemo Slows Growth of Uterine Serous Carcinoma

Trastuzumab Plus Chemo Slows Growth of Uterine Serous Carcinoma
In women with uterine serous carcinoma, a rare cancer subtype, combining the monoclonal antibody trastuzumab (Herceptin, Genentech) with a chemotherapy regimen such as carboplatin and paclitaxel has been shown to slow tumor growth. Although uterine s...

FDA Grants Approval to Rucaparib for Maintenance in Recurrent Ovarian Cancer

FDA Grants Approval to Rucaparib for Maintenance in Recurrent Ovarian Cancer
Rucaparib (Rubraca, Clovis Oncology Inc.) has received FDA approval for use as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-base...